Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Study sponsor: ArriVent BioPharma, Inc. · AVBP

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.